Frank Knudsen

Portfolio Manager at Acesion Pharma ApS

Frank Knudsen

Frank Knudsen

Portfolio Manager at Acesion Pharma ApS

Overview
RelSci Relationships

165

Number of Boards

15

Birthday

1958

Age

62

Contact Data
Trying to get in touch with Frank Knudsen? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Frank Knudsen likely has professional access to. A relationship does not necessarily indicate a personal connection.

General Partner at SEED Capital Management I/S

Relationship likelihood: Strong

Managing Partner at FIH Partners A/S

Relationship likelihood: Strong

Executive Chairman at Acesion Pharma ApS

Relationship likelihood: Strong

Chief Executive Officer at Oncology Venture ApS

Relationship likelihood: Strong

Founder & CSO at Conrig Pharma ApS

Relationship likelihood: Strong

Co-Founder at Contera Pharma ApS

Relationship likelihood: Strong

Professor at Chalmers University of Technology

Relationship likelihood: Strong

Former Chief Business Officer at NTG Nordic Transport Group A/S

Relationship likelihood: Strong

Co-Founder at Glycom A/S

Relationship likelihood: Strong

Professor at University of Hamburg

Relationship likelihood: Strong

Paths to Frank Knudsen
Potential Connections via
Relationship Science
You
Frank Knudsen
Portfolio Manager at Acesion Pharma ApS
Career History
Portfolio Manager
Current

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane Sørensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

Portfolio Manager
Current

Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark Von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark.

Portfolio Manager
Current

Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.

Boards & Committees
Director
Prior - 2012

MycoTeQ is working to ease the discovery process for the pharmaceutical industry in order to ensure a steady flow of new chemical entities into the pipelines of this industry.The aspiration of MycoTeQ is to build a healthy business and become the world leading external provider of new chemical entities from micro fungi. In order to succeed on these ambitious targets MycoTeQ will adhere to the highest professional and scientific standards and seek to build strong and long-lasting relationships with its partners and customers. The company was founded in October 2006 and is headquartered in Copenhagen, Denmark.

Director
Prior - 2010

Neurokey wants to become a leading drug development company in the critical care field.The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.

Director
Prior

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane Sørensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Frank Knudsen. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Frank Knudsen's profile does not indicate a business or promotional relationship of any kind between RelSci and Frank Knudsen.